IL-3 is a novel target to interfere with tumor vasculature.
about
c-Kit-Positive Adipose Tissue-Derived Mesenchymal Stem Cells Promote the Growth and Angiogenesis of Breast Cancer.miR-221/222 control luminal breast cancer tumor progression by regulating different targets.The role of HuR in the post-transcriptional regulation of interleukin-3 in T cells.Proton irradiation augments the suppression of tumor progression observed with advanced age.Comparative multiplex analysis of cytokines, chemokines and growth factors in follicular fluid of normoresponder women undergoing ovum donation with gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist protocols.Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression.Membrane-bound KIT ligand-targeting DNA vaccination inhibits mammary tumor growth.The Essential Role of Type I Interferons in Differentiation and Activation of Tumor-Associated Neutrophils.Activated Stat5 trafficking Via Endothelial Cell-derived Extracellular Vesicles Controls IL-3 Pro-angiogenic Paracrine Action.Unacylated ghrelin promotes skeletal muscle regeneration following hindlimb ischemia via SOD-2-mediated miR-221/222 expression.Multi-lineage differentiation and angiogenesis potentials of pigmented villonodular synovitis derived mesenchymal stem cells--pathological implication.IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the β-catenin pathway.A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.Cancer Stem Cell Metabolism and Potential Therapeutic Targets.
P2860
Q33720928-798254FF-8D08-41CC-AB51-06122488EC52Q33952998-368E3E93-C90F-490A-A7DE-C13B0D13EAB3Q35128284-58F21BE5-9406-4976-91CB-CBE5C7F96909Q35526292-B6889A28-F832-4DA7-B9F6-FECC1A6A0A39Q37370067-8F784D31-B966-4D2A-BC78-842F75506C6DQ37716544-B9D776C0-3FF7-4EAF-B9C0-978F0EAE37D9Q38627228-66A560D3-DAD9-40EA-A488-D29DB77D0A7AQ39076005-421C1C07-CD32-49DE-BD28-9F1AF6CA263CQ41169371-798FF15E-B147-449A-9CB6-7BE0546FA4F2Q41833851-BD41B713-ED10-40C3-B94C-C3FB2C3B3D65Q48075411-02DB6790-1FE9-4BDA-9E05-2628788C4732Q48122111-D63D0A9B-937C-4AD3-AB2E-C87A9DDEDE75Q48158203-AE8C8BDC-3F0E-4D0E-A765-519EB723FAD8Q55296899-91157AFF-9C81-4E20-AF5C-D1F2ED8310F8
P2860
IL-3 is a novel target to interfere with tumor vasculature.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
IL-3 is a novel target to interfere with tumor vasculature.
@en
IL-3 is a novel target to interfere with tumor vasculature.
@nl
type
label
IL-3 is a novel target to interfere with tumor vasculature.
@en
IL-3 is a novel target to interfere with tumor vasculature.
@nl
prefLabel
IL-3 is a novel target to interfere with tumor vasculature.
@en
IL-3 is a novel target to interfere with tumor vasculature.
@nl
P2093
P2860
P356
P1433
P1476
IL-3 is a novel target to interfere with tumor vasculature.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2011.204
P407
P577
2011-06-06T00:00:00Z